0.97 USD
+0.01 (+0.73%)
0.9887 USD
+0.02 (+1.93%)
Overall NXL gets a fundamental rating of 3 out of 10. We evaluated NXL against 187 industry peers in the Health Care Equipment & Supplies industry. While NXL has a great health rating, there are worries on its profitability. While showing a medium growth rate, NXL is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
NXL had negative earnings in the past year.
NXL had a negative operating cash flow in the past year.
NXL had negative earnings in each of the past 5 years.
In the past 5 years NXL always reported negative operating cash flow.
1.2 Ratios
NXL's Return On Assets of -169.31% is on the low side compared to the rest of the industry. NXL is outperformed by 90.91% of its industry peers.
NXL's Return On Equity of -182.01% is on the low side compared to the rest of the industry. NXL is outperformed by 71.12% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -169.31% | ||
| ROE | -182.01% | ||
| ROIC | N/A |
ROA(3y)-110.33%
ROA(5y)-801.91%
ROE(3y)-127.63%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
NXL's Gross Margin of 69.55% is fine compared to the rest of the industry. NXL outperforms 77.01% of its industry peers.
In the last couple of years the Gross Margin of NXL has grown nicely.
NXL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 69.55% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.73%
GM growth 5Y2.21%
2. Health
2.1 Basic Checks
NXL does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, NXL has more shares outstanding
The number of shares outstanding for NXL has been increased compared to 5 years ago.
There is no outstanding debt for NXL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of 1.02, we must say that NXL is in the distress zone and has some risk of bankruptcy.
NXL has a Altman-Z score of 1.02. This is comparable to the rest of the industry: NXL outperforms 52.94% of its industry peers.
There is no outstanding debt for NXL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.02 |
ROIC/WACCN/A
WACC8.78%
2.3 Liquidity
A Current Ratio of 13.48 indicates that NXL has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 13.48, NXL belongs to the top of the industry, outperforming 97.33% of the companies in the same industry.
A Quick Ratio of 13.03 indicates that NXL has no problem at all paying its short term obligations.
The Quick ratio of NXL (13.03) is better than 97.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 13.48 | ||
| Quick Ratio | 13.03 |
3. Growth
3.1 Past
NXL shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 0.33%.
The Revenue has decreased by -3.09% in the past year.
The Revenue has been decreasing by -4.05% on average over the past years.
EPS 1Y (TTM)0.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.48%
Revenue 1Y (TTM)-3.09%
Revenue growth 3Y5.39%
Revenue growth 5Y-4.05%
Sales Q2Q%-49.58%
3.2 Future
The Earnings Per Share is expected to grow by 16.65% on average over the next years. This is quite good.
NXL is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 95.89% yearly.
EPS Next Y19.67%
EPS Next 2Y16.65%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year34.3%
Revenue Next 2Y95.89%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for NXL. In the last year negative earnings were reported.
Also next year NXL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as NXL's earnings are expected to grow with 16.65% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.65%
EPS Next 3YN/A
5. Dividend
5.1 Amount
NXL does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
0.97
+0.01 (+0.73%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners3.78%
Inst Owner Change-46.37%
Ins Owners12.78%
Ins Owner Change5.82%
Market Cap18.09M
Revenue(TTM)157.00K
Net Income(TTM)-8.68M
Analysts80
Price Target4.08 (320.62%)
Short Float %1.7%
Short Ratio0.06
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)11.01%
Min EPS beat(2)-7.26%
Max EPS beat(2)29.28%
EPS beat(4)1
Avg EPS beat(4)-39.38%
Min EPS beat(4)-131.02%
Max EPS beat(4)29.28%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)21.47%
Min Revenue beat(2)-55.07%
Max Revenue beat(2)98.02%
Revenue beat(4)2
Avg Revenue beat(4)12.01%
Min Revenue beat(4)-55.07%
Max Revenue beat(4)98.02%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 115.23 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 3.79 | ||
| P/tB | 4.06 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.66
EYN/A
EPS(NY)-0.39
Fwd EYN/A
FCF(TTM)-0.27
FCFYN/A
OCF(TTM)-0.27
OCFYN/A
SpS0.01
BVpS0.26
TBVpS0.24
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -169.31% | ||
| ROE | -182.01% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 69.55% | ||
| FCFM | N/A |
ROA(3y)-110.33%
ROA(5y)-801.91%
ROE(3y)-127.63%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.73%
GM growth 5Y2.21%
F-Score2
Asset Turnover0.03
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 92.42% | ||
| Cap/Sales | 11.66% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 13.48 | ||
| Quick Ratio | 13.03 | ||
| Altman-Z | 1.02 |
F-Score2
WACC8.78%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.48%
EPS Next Y19.67%
EPS Next 2Y16.65%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-3.09%
Revenue growth 3Y5.39%
Revenue growth 5Y-4.05%
Sales Q2Q%-49.58%
Revenue Next Year34.3%
Revenue Next 2Y95.89%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-36.12%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-32.76%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-32.27%
OCF growth 3YN/A
OCF growth 5YN/A
NEXALIN TECHNOLOGY INC / NXL FAQ
Can you provide the ChartMill fundamental rating for NEXALIN TECHNOLOGY INC?
ChartMill assigns a fundamental rating of 3 / 10 to NXL.
What is the valuation status of NEXALIN TECHNOLOGY INC (NXL) stock?
ChartMill assigns a valuation rating of 0 / 10 to NEXALIN TECHNOLOGY INC (NXL). This can be considered as Overvalued.
How profitable is NEXALIN TECHNOLOGY INC (NXL) stock?
NEXALIN TECHNOLOGY INC (NXL) has a profitability rating of 1 / 10.
What is the financial health of NEXALIN TECHNOLOGY INC (NXL) stock?
The financial health rating of NEXALIN TECHNOLOGY INC (NXL) is 7 / 10.